0000950170-24-002938.txt : 20240108 0000950170-24-002938.hdr.sgml : 20240108 20240108161514 ACCESSION NUMBER: 0000950170-24-002938 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240104 FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sinha Vikas CENTRAL INDEX KEY: 0001337845 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 24520294 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACUETICALS, INC. STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 ownership.xml 4 X0508 4 2024-01-04 0001754068 Allovir, Inc. ALVR 0001337845 Sinha Vikas C/O ALLOVIR, INC. 1100 WINTER STREET WALTHAM MA 02451 true true true false See Remarks false Common Stock 2024-01-04 4 S false 961 0.639 D 1166788 D Common Stock 16674766 I Shares held by ElevateBio LLC Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Officer Title: President and Chief Financial Officer /s/ Brett Hagen, as Attorney-in-Fact 2024-01-08